### Tables

1.1 Classification of 153 Canadian studies from 2001 to 2006 15
1.2 Costs and effects for alternative gallstone treatments 18
1.3 Cost and effect per patient for worksite care and regular care 19
1.4 Detection rates for successive stool guaiac tests 22
1.5 Bednet usage in Kenya in the Millennium Village and in the MV region 25
1.6 Evaluation of neo-natal intensive care treatment 26
2.1 Short run production function for lengths of stay 35
2.2 Short run cost curves for lengths of stay 35
2.3 Long run production function for lengths of stay 36
2.4 Discount factors for alternative time horizons and interest rates 38
2.5 Avoidable costs in SEK of liver cirrhosis for women compared to base year, ten years 39
2.6 Reference requirements for five treatments (per 100 bed-days) 45
2.7 Costs and cost-effectiveness ($C/E$) for three live kidney donor transplant treatments 46
2.8 Inflation-controlled hospital costs for total knee arthroplasty 48
2.9 Total costs and cost profiles of 17 prevention interventions targeting CSWs in Tamil Nadu and Andhra Pradesh in India in 2002–03 51
2.10 Lifetime costs of HIV 54
2.11 Costs of different treatments before and after treatment 56
2.12 Costs of liver cirrhosis for women compared to base year, 24 years 58
3.1 Percentage of cases where RCC-estimated costs are within 10 percent of RVU-estimated costs 70
3.2 DATCAP costs from 110 substance abuse treatment programs 72
3.3 Estimates of economies of scope for Danish hospitals 74
3.4 DRGs that give different profitability outcomes using RVUs and RCCs 76
3.5 Resource based relative values and Medicare charges 78
3.6 Estimates of the share of the physician’s bill that counts as costs 81
3.7 DATCAP costs for 302 clients and 440 client episodes 82
3.8 Human resource cost per chest X-ray films 84
3.9 Hypothetical translation of a patient’s bill: charges to costs 85
3.10 Hypothetical use of cost centers 85
4.1 Consequences of increased taxes in consumer surplus loss to drinkers and lives saved 102
4.2 Literature estimates of costs and benefits on a comparable basis 105
4.3 Comparison of optimal and actual policies for schistomiasis 109
4.4 Effect of education of household members on health care outcomes (change in probabilities) 111

Robert J. Brent - 9781781004593
Downloaded from Elgar Online at 08/19/2019 03:21:45AM via free access
4.5 Sensitivity analysis for JE vaccination program in Thailand 112
5.1 Estimates of the marginal cost of funds for the US federal government (\(MCF_p\)) 125
5.2 Estimates of the marginal cost of funds for US state governments (\(MCF_s\)) 126
5.3 Estimates of the marginal cost of funds for 38 African countries 128
5.4 Estimates of the marginal cost of funds using the ratio of average to median household income 130
5.5 Net benefits of a permanent $1 increase in social security (1985–2060) 134
5.6 Tax rates and MCFs under different scenarios 137
5.7 The data on prices, quantities and costs for non-federal general hospitals (1990) 138
5.8 Net benefits of privatization of non-federal general hospitals in the US 139
5.9 Weighted costs of systems of psychiatric care in Massachusetts 140
5.10 Evaluation of case management programs 142
5.11 The relation between the excess burden and the level of the tax rate 144
6.1 Hypothetical example of the cost-effectiveness paradigm 152
6.2 Hypothetical example of the cost-effectiveness paradigm with competing choices 153
6.3 Cost and effect per patient for worksite care and regular care 154
6.4 Inclusion and exclusion criteria 167
6.5 Optimal spending and the \(C/E\) ratio: men, income = $18,000 172
6.6 Federal evaluation of state psychiatric hospital care 173
6.7 Determinants of decisions concerning alcohol treatment effectiveness 175
6.8 Effects and costs of screening for cervical cancer using the Pap smear 176
6.9 Participant willingness to pay for web-based versus face-to-face course delivery modes 177
7.1 Programs with varying timing of costs and benefits 185
7.2 Programs with a delayed timing of costs and effects 187
7.3 Programs with costs that vary by individuals 189
7.4 Confidence intervals for a typical cost-effectiveness calculation using three alternative methods 194
7.5 Using the net-benefit regression results to create cost-effectiveness acceptability curves for the Skilled Care Initiative, Burkina Faso 197
7.6 Wage equation estimates 200
7.7 Estimates of social discount rates for the period 1965–89 202
7.8 Effect of selected variables on calorie consumption 206
7.9 Estimates and 95 percent lower and upper confidence limits for \(E/C\) in the SRTI trial 208
7.10 Confidence intervals for incremental cost-effectiveness ratios, ICD vs EP 209
8.1 Comparative cost-utility results for selected programs 219
8.2 NICE decisions ranked by incremental cost-effectiveness ratio 222
8.3 Calculations of QWB with and without treatment 225
8.4 Top 10 priorities of the Oregon HSC initially and subsequently 227
8.5 Measures of economic evaluation of neonatal intensive care by birth weight 230
8.6 Some extracts of cost for QALYs for competing treatments 232
8.7 NICE decisions ranked by ICER with their associated probability of rejection 236
8.8 Balance sheet of expected effect of demonstration program on number of people covered, services covered and financial costs 238
8.9 Cost-effectiveness ratio estimates of THA and other procedures 242
9.1 Utility values using TTO for patients versus general public by duration 248
9.2 Mean time trade-off and visual analogue scores 250
9.3 Intra-class correlation using time trade-off 251
9.4 The Rosser and Kind index of health status 254
9.5 Valuation of EuroQol health states 261
9.6 Annual transition probabilities for monotherapy 264
9.7 Calculation of life expectancy over 20 cycles for monotherapy for the case study Markov model 265
9.8 Selected results from comparative valuation studies 267
9.9 Mean SG, TTO and RS quality weights for health state E 268
9.10 The seven health profiles included in the experiment 269
9.11 Implied rankings of the seven health profiles for different quality weights 269
9.12 Mean Spearman rank correlation coefficients between the direct rankings and the predicted rankings of RS, TTO and SG 270
9.13 Results for visual function and utility values according to visual acuity 271
9.14 Patients willing to trade time for improved vision (TTO method) and risk immediate death for improved vision (SG method) 272
9.15 Ratings of standardized health states 273
9.16 HUI Mark 2 classification scheme 275
9.17 Change in health state utility after hearing aid fitting and ICER 276
9.18 Coefficient estimates and significance levels of the determinants of HIV/AIDS utilities 278
10.1 Revised disability classes for the Global Burden Disease Study based on the results of the PTO protocol used at the Geneva meeting on disability weights 287
10.2 DALY losses by age at death in Uganda 288
10.3 Comparison of DALYs versus deaths in demographically developing countries by categories of disease 288
10.4 Global disability adjusted life years 1990 to 2010 289
10.5 Life expectancies at birth and after intervention (remaining years) 289
10.6 Utilities for health states with knee condition 293
10.7 The ICECAP-O instrument, attributes and values 298
10.8 The number of lives, life years and QALYs saved among 50-year-olds and 70-year-olds equivalent to saving one life, life year and QALY among 30-year-olds 302
10.9 Incremental cost-effectiveness analysis for sleeping sickness in Uganda 303
10.10 Apparent impact of HIV on mortality: DALYs as compared with HealYs, 1990 305
10.11 Comparison of restrained and non-restrained clients 306
10.12 Correlations between ICECAP-O, well-being indices and EuroQoL 308
<table>
<thead>
<tr>
<th>Table</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.1</td>
<td>The value of a quality adjusted life year (1997 dollars) by study type</td>
</tr>
<tr>
<td>11.2</td>
<td>WTP per QALY for each health state</td>
</tr>
<tr>
<td>11.3</td>
<td>WTP per QALY in six countries</td>
</tr>
<tr>
<td>11.4</td>
<td>Costs and benefits of alternative mental health programs</td>
</tr>
<tr>
<td>11.5</td>
<td>Age-group specific VSLs</td>
</tr>
<tr>
<td>11.6</td>
<td>Comparison of the VSLs using the cross-sections with that of the cohort analysis</td>
</tr>
<tr>
<td>11.7</td>
<td>Costs and benefits of the 55 mph speed limit decision using different numeraires</td>
</tr>
<tr>
<td>11.8</td>
<td>Summary of Clear Skies initiative benefits based on EPA VSLs versus VSLs estimated by Aldy and Viscusi</td>
</tr>
<tr>
<td>12.1</td>
<td>Estimated value of waiting list time</td>
</tr>
<tr>
<td>12.2</td>
<td>Monetary valuations of NHS nursing home care and hospital care for respondents with a preference for NHS nursing home care</td>
</tr>
<tr>
<td>12.3</td>
<td>Conjoint analysis results for the choice of medication versus surgery for the management of miscarriage</td>
</tr>
<tr>
<td>12.4</td>
<td>The costs and benefits of mobile screening in NSW</td>
</tr>
<tr>
<td>13.1</td>
<td>Price elasticities for health in Peru by income quintile</td>
</tr>
<tr>
<td>13.2</td>
<td>Weighted net benefits of case management programs with alternative sets of distribution weights</td>
</tr>
<tr>
<td>13.3</td>
<td>Number responding and stated willingness to pay as percentage of family income</td>
</tr>
<tr>
<td>13.4</td>
<td>Equivalence numbers in questionnaires without and with explicit arguments</td>
</tr>
<tr>
<td>13.5</td>
<td>Numbers weights for severity of illness corresponding to PTO estimates</td>
</tr>
<tr>
<td>13.6</td>
<td>Aggregate results: percentage change in total demand accounted for by each income quintile and consumers’ welfare loss as a percentage of income by income quintile</td>
</tr>
<tr>
<td>13.7</td>
<td>Disaggregated results for quantity reductions ( (D_i / D) ) by quintile</td>
</tr>
<tr>
<td>13.8</td>
<td>Disaggregated results for benefit losses as a percentage of income ( (B_i / Y) ) by quintile</td>
</tr>
<tr>
<td>13.9</td>
<td>Disaggregated costs and benefits of raising user fees in Peru by quintile</td>
</tr>
<tr>
<td>13.10</td>
<td>The weight for each of the three social objectives behind public hospital construction decisions in Turkey</td>
</tr>
<tr>
<td>14.1</td>
<td>HIV/AIDS by region, December 2012</td>
</tr>
<tr>
<td>14.2</td>
<td>Costs of MC interventions relative to treating infections not averted due to MC</td>
</tr>
<tr>
<td>14.3</td>
<td>Cost–benefit outcomes for VCT options</td>
</tr>
<tr>
<td>14.4</td>
<td>Net benefits per person of ARVs on depressed and non-depressed groups by era</td>
</tr>
<tr>
<td>14.5</td>
<td>WTP for an HIV/AIDS vaccine according to income</td>
</tr>
</tbody>
</table>